Introduction


Oncology medicines reimbursed in France have a fixed price whereas the benefits vary across patient groups.
Pricing models aligned to the clinical benefit open an interesting concept, but they need to be supported by reliable and standardised metrics aligned with health authorities 'expectation.
The Personalised Reimbursement Models (PRM) project is a global Roche project inspired by the Italian pricing system.
In France, the PRM approach aims to establish an infrastructure to collect routinely existing data in order to be used as input for pricing models.
A pilot phase has been achieved in 2014 to validate the feasibility of the of the project.
Pilot phase

All metastatic breast cancer (mBC) patients at 14 pilot centres recorded in the Electronic Pharmacy Record (EPR) system with at least one trastuzumab claim between January 2011 to October 2014 that were not enrolled in a clinical trial were selected ( Figure  1 ).
Data related to demographics, disease description, drug usage and clinical outcomes were collected in the EPR (Figure 2 ). These data were controlled, cleaned and centralised in an anonymous and secure way through an accredited hosting provider.
Patients were followed from the index date (first Trastuzumab claim) until six months after last date any drug prescription recorded in the EPR (Figure 1 ).
Scale-up phase

The recruitment of around 100 additional centres began in January 2015  A cluster sampling method by region and type of centres (university hospitals, general hospitals, anti-cancer centres and private clinics) has been used to ensure clinical practice representativeness.
The retrospective longitudinal follow-up will be updated by routinely data extractions every 4 months. The missing variables (e.g response to treatment) have been identified in other data sources within centres or could be added to the EPR by updating and enhancing the health information systems.
The project has got interest from the French healthcare authorities. It is built to take into account the expectations of all involved stakeholders.
The scope of the project has been extended to all HER2 breast cancer patients treated.
It could be extended to other indications in the following months / years.
 PRM output will be used for patients benefit and centres involved in the project by valorisation of existing data (Figure 2 ). 
Conclusion

Pilot study has validated technical and legal feasibility of the PRM infrastructure implementation and outputs quality.
Over time, through this automatic data collection, PRM will deliver robust and standardised real world evidence that could be used to implement models that will support more flexible pricing strategies and help ensure patient access to innovative treatments delivered in different indications. This tool extends the number of agreements the French Authorities could discuss with pharmaceutical companies.
